Vantus Wealth LLC Buys New Shares in Eli Lilly and Company $LLY

Vantus Wealth LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 797 shares of the company’s stock, valued at approximately $857,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the last quarter. 10Elms LLP grew its holdings in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth $33,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark now covers Eli Lilly’s full obesity drug portfolio, including the newly approved oral therapy Foundayo and injectable Zepbound. With all three major U.S. PBMs covering Lilly’s obesity medicines, the company gets broader insurance access and a stronger commercial outlook for its weight-loss franchise. PBM Coverage Of Eli Lilly Obesity Drugs Reshapes Growth And Pricing Outlook
• Positive Sentiment: Lilly announced a major Phase 3 win for Retevmo (selpercatinib), which cut the risk of recurrence or death by 83% in early-stage RET fusion-positive lung cancer. The data could expand the drug’s use and add to Lilly’s oncology growth pipeline. Unit of China’s Haisco, Eli Lilly sign collaboration, licensing deals
• Positive Sentiment: The company also announced new licensing and collaboration deals in Asia, including agreements with Hanmi and Haisco. Investors may view the deal-making as evidence that Lilly is actively building its next wave of products beyond obesity drugs. Lilly Continues Its Acquisition Spree, Inks Two Asia Partnerships Today
• Neutral Sentiment: Several commentary pieces highlighted Lilly as one of the market’s top momentum stocks, and noted bullish analyst sentiment and strong Q1 revenue growth. These reports reinforce positive expectations, but they do not add materially new fundamentals. These 8 Words From Eli Lilly’s CEO Have Wall Street Turning Bullish
• Neutral Sentiment: One industry update noted Novo Nordisk’s oral GLP-1 pill is still outselling Lilly’s competing tablet, though growth is slowing. That suggests the obesity market remains highly competitive even as Lilly expands access. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
• Negative Sentiment: There was also a widely circulated note that Lilly shares had been trading down earlier in the period, but the article did not point to a new company-specific problem. Insider selling data in one report may also weigh on sentiment, though it is not necessarily a near-term fundamental issue. Eli Lilly and Company (NYSE:LLY) Trading Down 1.9% – What’s Next?

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LLY. Guggenheim reissued a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Cantor Fitzgerald raised their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Argus raised their price target on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Trading Down 2.3%

Shares of LLY opened at $1,079.96 on Tuesday. The firm’s 50-day moving average price is $959.18 and its 200-day moving average price is $1,010.74. The firm has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 38.36, a PEG ratio of 1.21 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,149.10.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.